Nutex Health Inc. (NUTX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Nutex Health Inc. is a physician-led healthcare services company operating 27 hospital facilities across 12 states (Hospital Division) and a risk-bearing population health management division. The company operates as an out-of-network provider, heavily utilizing the Independent Dispute Resolution (IDR) process under the No Surprises Act to secure reimbursement from insurers.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $216.5 million | $211.8 million |
| Net Income (GAAP) | $62.8 million | $50.8 million |
| Net Income Attributable to Nutex | $46.8 million | $21.2 million |
| Diluted EPS | $6.52 | $3.33 |
| Operating Cash Flow | $75.5 million | $51.0 million |
| Cash and Equivalents (End of Period) | $207.3 million | $84.7 million |
| Total Debt (Gross) | $41.3 million | $43.5 million |
| Adjusted EBITDA | $57.6 million | $72.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 2.2% year-over-year, driven by a 3.1% increase in patient visits and higher cash collections, partially offset by a decrease in net revenue per visit.
- Profitability Surge: Net income attributable to Nutex more than doubled (120% increase) primarily due to a $31.6 million reduction in stock-based compensation expense. In Q1 2026, stock-based compensation resulted in a gain of $3.9 million, compared to an expense of $27.6 million in Q1 2025.
- Arbitration Costs: The cost of arbitration for hospital and professional services rose significantly to $46.1 million in Q1 2026 from $26.3 million in Q1 2025. This increase contributed to a 24% decline in the Hospital Division's gross profit margin despite higher visit volumes.
- Capital Allocation: The company aggressively returned capital to shareholders, repurchasing and retiring 200,444 shares for approximately $31.7 million during the quarter.
Outlook, Risks, and Management Commentary
- Arbitration Strategy: Management continues to rely on the IDR process, utilizing third-party vendor HaloMD to manage claims. While arbitration costs have risen, the company notes that providers prevailed in approximately 88% of payment determinations in the first half of 2025.
- Share Repurchases: The company completed a $25.0 million repurchase program in August 2025 and initiated a new $25.0 million program in March 2026. Approximately $23.0 million remains available under the new program.
- Legal Proceedings:
- Securities Litigation: A putative class action alleges misstatements regarding the third-party arbitration vendor and internal controls. A motion to dismiss is pending.
- Earn-Out Disputes: Former owners of under-construction hospitals are disputing the calculation of earn-out shares, specifically regarding adjustments for the 2024 reverse stock split. The company disputes these claims, but an adverse outcome could cause significant dilution.
- Regulatory Risks: The company faces ongoing uncertainty regarding the No Surprises Act, including potential legislative changes to enforcement penalties and federal court rulings on the Qualifying Payment Amount (QPA) methodology.
Investor Verification Checklist
- Arbitration Economics: Verify the sustainability of the 88% win rate in IDR proceedings against the rising cost of arbitration ($46.1M in Q1) and its impact on long-term gross margins.
- Stock-Based Compensation Volatility: Assess the reliability of future earnings given the swing from a $27.6M expense to a $3.9M gain in stock-based compensation, which was the primary driver of the reported net income increase.
- Dilution Risk: Review the status of the earn-out disputes with former doctor owners; a loss could trigger the issuance of significant additional shares (estimated at ~19.8% of outstanding shares for completed hospitals).
- Liquidity vs. Debt: Confirm the company's ability to service its debt and lease obligations ($41.3M debt + significant lease liabilities) while maintaining its aggressive share repurchase program.